An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.

J Med EconJul 14, 2026 (epub)
Clinical ResearchOncology (Medical)

Toby A Eyre, Leyla Mohseninejad, Lianne Barnieh et al.

✦ AI-curated · Sources linked

In 30 seconds

This study conducted an unanchored matching-adjusted indirect comparison to evaluate the efficacy of zanubrutinib versus ibrutinib in patients with relapsed/refractory mantle-cell lymphoma (R/R MCL). The analysis included individual patient data from zanubrutinib trials (n=118) and pooled data from ibrutinib trials (n=370). Results indicated that zanubrutinib significantly improved progression-free survival (HR=0.63) and overall survival (HR=0.46) compared to ibrutinib.

Key findings

  • Zanubrutinib showed a hazard ratio of 0.63 for progression-free survival compared to ibrutinib.
  • Overall survival was significantly better with zanubrutinib, with a hazard ratio of 0.46.
  • Statistical significance was achieved with p-values of 0.0044 for progression-free survival and 0.0005 for overall survival.

Why it matters

Understanding the comparative efficacy of treatments for relapsed/refractory mantle-cell lymphoma is crucial for optimizing patient outcomes. This study provides insights that may influence treatment decisions in clinical practice.

Source

PubMed · PMID 42452801

Published in J Med Econ. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.